Please ensure Javascript is enabled for purposes of website accessibility

Allergan Sued by BTL Over False Advertising Claims Regarding Muscle-Toning Product

By Mark Prvulovic - Feb 20, 2020 at 6:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant stands accused of making false and misleading product comparisons.

The privately owned BTL Industries officially announced that it had filed a lawsuit against Allergan (AGN), claiming that the company had run a false and deceptive advertising campaign against BTL's non-invasive muscle-toning product.

According to details from the lawsuit, Allergan's marketing materials featured a number of misleading comparisons between the company's CoolTone product and BTL's Emsculpt product, claiming that CoolTone had a number of performance advantages over its competitor. The lawsuit goes on to specify that many of these claims are either incorrect or misleading, such as Allergan's statements regarding the magnetic intensity of its products, as well as the implication that magnetic intensity is a direct measure of efficiency.

A picture of a gavel, law books, and a scale on a table.

Image source: Getty Images.

"Long before bringing their product to the market, Allergan knowingly made false, deceptive, and misleading descriptions of fact concerning the nature, characteristics, and qualities of the EMSCULPT device as compared to their product," said Filip Donner, Director of BTL Industries in a press release. If BTL can prove its case in court, then it will expect monetary damages to compensate both its legal fees, as well as damages done.

Previous litigation

This isn't the first time that Allergan and BTL have had legal issues. Back in December, BTL filed a separate patent-infringement lawsuit against the pharmaceutical giant in regards to the CoolTone device, arguing that the design infringes on BTL's patents. Both the misleading marketing case, as well as the patent infringement case were filed in the U.S. District Court for the District of Delaware.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.